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Abstract
Background New-onset diabetes after transplantation
(NODAT) is a significant co-morbidity following kidney
transplantation. Lower post-transplant serum magnesium
levels have been found to be an independent risk factor for
NODAT in adult kidney transplant recipients.
Methods We undertook a retrospective analysis of risk factors
for NODAT in pediatric renal transplant recipients at our in-
stitution with the aim of determining if hypomagnesemia con-
fers a significant risk of developing NODAT in this patient
population.
Results A total of 173 children with a median age at trans-
plantation of 7.0 (range 1.3–17.5) years were included.
Hypomagnesemia was found to be a significant independent
risk factor for NODAT (p = 0.01). High trough tacrolimus
levels were also independently associated with NODAT
(p < 0.001). There was no significant association between
NODAT and body mass index at the time of transplantation,
monthly cumulative steroid dose or post-transplant cytomeg-
alovirus viremia (p = 0.9, 0.6 and 0.7, respectively).
Conclusions This study identifies hypomagnesemia as a sig-
nificant independent risk factor for the development of
NODAT in pediatric renal transplant recipients. Given the
clear association between hypomagnesemia and NODAT in
both adults and children following renal transplantation, fur-
ther studies are merited to clarify the etiology of this associa-
tion and to examine the effect of magnesium supplementation
on NODAT.
Keywords Kidney transplantation . Diabetes .
Hypomagnesemia . Children . Tacrolimus
Introduction
New-onset diabetes after transplantation (NODAT) is a signif-
icant co-morbidity in kidney transplant recipients. It compro-
mises both renal transplant and patient survival [1]. The inci-
dence of NODAT is increasing in pediatric renal transplant
recipients, although it remains less prevalent than in the adult
population [2]. NODAT adds to the burden of cardiovascular
disease observed in children following kidney transplantation
[3, 4]. A deeper understanding of this co-morbid disease is
needed in order to inform strategies to aid its prevention and
improve clinical management.
In adult kidney transplant recipients, a number of indepen-
dent risk factors for NODAT have been identified, including
obesity, family history of diabetes, ethnicity, older age, infec-
tions and episodes of acute rejection [5–9]. Known risk factors
for NODAT in pediatric kidney transplant recipients include
increasing age, body mass index (BMI) of >30 kg/m2, ta-
crolimus exposure and primary cytomegalovirus (CMV)
mismatch [2].
Lower post-transplant serum magnesium levels have
been found to be an independent risk factor for NODAT
in adult kidney transplant recipients [10]. Whilst hypomag-
nesemia is prevalent in children following renal transplan-
tation [11], its association with NODAT has not previously
been examined.
We undertook a retrospective analysis of risk factors for
NODAT in 173 pediatric renal transplant recipients at our
institution with the aim of determining if hypomagnesemia
confers a significant risk of developing NODAT in children.
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Methods
A retrospective analysis of a clinical database of pediatric
renal transplant recipients transplanted and followed at
our institution was undertaken. Patients transplanted after
1 January 2000 with a minimum 3 months of follow-up
data, including laboratory test results, were eligible.
Exclusion criteria were insulin therapy prior to transplant for
diabetes mellitus or metabolic disease. Data were pseudo-
anonymized for analysis. Local research ethics approval was
obtained.
ANODATepisode was defined as two ormore consecutive
random blood glucose measurements of >11.1 mmol/l taken
on separate days, excluding the first 7 days post-transplanta-
tion. CMV viremia was defined by positive detection of CMV
PCR DNA in whole blood. A 30-day moving average trough
tacrolimus level of >12 ng/l was defined as high.
The cumulative probability of NODAT over time was
expressed using survival analysis. Cox proportional hazard
models were fitted to determine the significance of various
risk factors for NODAT. Covariates included patient age,
BMI, plasma magnesium levels, trough tacrolimus levels, re-
cipient CMV viremia post-transplant, cumulative monthly
dose of prednisolone and mutations in the hepatocyte nuclear
factor-1beta (HNF-1B) gene known to be causative of renal
cysts and diabetes (RCAD) syndrome.
Monthly (30 day) moving average values of continuous
covariates commencing day 30 post-transplantation were used
to determine their effect on NODAT risk as time progresses.
Colinearity between continuous covariates was analyzed
using Pearson’s correlation.
All analyses were performed using Stata IC, version 13
(StataCorp LP, College Station, TX).
Results
A review of the medical files resulted in the identification of
175 children transplanted between 1 January 2000 and 31
May 2016 and currently followed at our center with sufficient
data for analysis and therefore eligible for entry to our study.
Two patients were subsequently excluded as they were receiv-
ing insulin therapy prior to transplantation. The median age at
transplantation was 7.0 (range 1.3–17.5) years, and 101 (58%)
of the children were male. The median follow-up was 4.2
(range 0.6–15.9) years.
Of the 173 pediatric renal transplant recipients enrolled in
our study, 20 (11%) experienced NODAT, with eight (5%)
children requiring insulin therapy for >12 months. The medi-
an time to detection of NODAT was 9 (range 9–551) days.
Three patients developed NODAT between 8 and 30 days
post-transplantation, one of whom required insulin therapy
for >12 months.
Five (3%) of the 173 children had sustained hypomagne-
semia on the 30-day moving average assessments. The medi-
an BMI at the time of transplantation was 17.9 (range 13.8–
33.6) kg/m2. Median monthly moving average trough tacroli-
mus levels were 3.9 (range 2.0–15.4) ng/l. Forty one (24%)
children had high monthly moving average trough tacrolimus
levels, and 49 (31%) children had CMV viremia post-
transplantation during the study period. The median cumula-
tive prednisolone dose was 793 (range 720–3430) mg/m2
body surface area for the first 30 days post-transplantation.
Ten (6%) children with ultrasound findings consistent with
RCAD were offered genetic testing of HNF-1B, and a causa-
tive HNF-1B gene deletion was found in one child.
Hypomagnesemia was found to be a significant indepen-
dent risk factor for developing NODAT (p = 0.01;Fig. 1a).
Fig. 1 Cumulative incidence of
new-onset diabetes after
transplantation (NODAT) in
children with normal and low
plasma magnesium (Mg) levels
(a) and normal and high trough
tacrolimus levels (b). FK
tacrolimus
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High trough tacrolimus levels were also independently asso-
ciated with NODAT (p < 0.001; Fig. 1b). No significant asso-
ciation between NODAT and post-transplant CMV viremia
was observed (p = 0.7; Table 1). Similarly, children’s BMI at
the time of transplantation was not significantly associated
with NODAT (p = 0.9; Table 1). No association between cu-
mulative 30-day prednisolone dose normalized to body sur-
face area and NODAT was observed (p = 0.6; Table 1).
Insufficient genetic data were available to reliably determine
the association between HNF-1B mutations and NODAT.
The association between hypomagnesemia and tacroli-
mus levels was examined in order to determine if these
risk factors for NODAT were independent. Of the 41 chil-
dren with high trough tacrolimus levels, three (7%) had
hypomagnesemia. No significant association was found be-
tween patients with hypomagnesemia and high trough ta-
crolimus levels (analysis of variance p = 0.06). A small
negative linear correlation between serum magnesium
levels and trough tacrolimus levels was observed
(r = −0.09, p < 0.001; Fig. 2).
Discussion
This study identifies hypomagnesemia as a significant inde-
pendent risk factor for NODAT in pediatric renal transplant
recipients. High trough tacrolimus levels confer additional
risk, which was found to be independent of hypomagnesemia.
Neither BMI, patient age or CMV viremia were significantly
associated with NODAT in this cohort.
Several risk factors for NODAT in pediatric renal transplant
recipients have been reported in previous studies. These in-
clude increasing age, BMI, tacrolimus exposure and primary
CMV mismatch [2]. Some of these risk factors were corrobo-
rated in the current study, whilst others were not replicated in
our data. The association of calcineurin inhibition with
NODATwas clearly seen in the present study. The cumulative
effect of high tacrolimus levels significantly increased the risk
of NODAT in this pediatric cohort. Other previously reported
NODAT risk factors were not replicated in the present analy-
sis, namely age at transplantation, BMI and CMV viremia.
This discordance may be related to limitations of the present
Table 1 Risk factors for new-
onset diabetes after
transplantation as determined by
Cox proportional hazards model
Risk factor Hazard ratio 95% Confidence interval p value
High 30-day moving average trough tacrolimus level 5.9 2.2–15.3 <0.001
Low 30-day moving average magnesium level 4.6 1.4–14.6 0.01
Body mass index at transplantation 1.0 0.9–1.1 0.9
Cytomegalovirus viremia post transplantation 0.8 0.3–2.2 0.7
Age at transplantation 0.9 0.8–1.1 0.8
Cumulative 30-day prednisolone dose 0.9 1.0 0.6
NODAT new onset diabetes after transplantation
Fig. 2 Linear relationship
between serum magnesium and
trough tacrolimus levels. (Best fit
linear regression line with 95%
confidence intervals shown)
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study, such as its retrospective design and relatively small
numbers, both of which may compromise detection of a true
association between risk factors and the development of
NODAT. Alternatively, the lack of reproducibility of some
NODAT risk factors in the current data may simply reflect
the absence of a robust association in children.
The effect of transplant immunosuppression regimens on
the risk of NODAT remains debated. Randomized trials of
early corticosteroid withdrawal in adult renal transplant recip-
ients showed limited impact on NODAT [12, 13], whereas
lower rates of hyperglycemia and NODAT were reported in
pediatric renal transplant recipients following early corticoste-
roid withdrawal [14, 15]. The current study showed no signif-
icant association between monthly cumulative steroid expo-
sure and NODAT. The lack of an observed relationship may
relate to predominance of other NODAT risk factors, such as
tacrolimus exposure or hypomagnesemia. Alternatively, a true
association between corticosteroid exposure and NODAT
may be confounded by the limitations of the current study
outlined below.
To the authors’ knowledge, this is the first report of the
association between hypomagnesemia and NODAT in pediat-
ric renal transplant recipients. A clear link with NODAT has
been established in adult kidney transplant recipients [10,
16–18]. The pathophysiological mechanism underlying the
association between hypomagnesemia and NODAT has not
yet been elucidated. Several observations suggest that a causal
relationship is biologically plausible. Over two decades ago,
magnesium was found to be an important cofactor in pancre-
atic insulin secretion and cellular glucose uptake [19, 20].
Magnesium deficiency has been shown to promote insulin
resistance [21–23]. Supplementation of magnesium is report-
ed to improve glucose tolerance in animal and clinical studies
in non-transplant patients with diabetes mellitus [24–30]. A
definitive causal link between hypomagnesemia and NODAT
remains to be found.
Alternatively, the association between hypomagnesemia
and NODAT may not be causal. Both hypomagnesemia and
diabetes can result from mitochondrial dysfunction, as found
in a large pedigree with hypomagnesemia and metabolic syn-
drome [31]. Mitochondrial dysfunction could therefore under-
lie the association between hypomagnesemia and NODAT. In
kidney transplant recipients, tacrolimus can cause secondary
mitochondrial respiratory chain dysfunction [32–34]. This
could therefore be the common link in the association between
hypomagnesemia and NODAT. Further work is needed to
definitively establish whether the link between hypomagnese-
mia and NODAT in pediatric renal transplant recipients is
purely an association, or a causal relationship.
Given the significant association of both hypomagnesemia
and high trough tacrolimus levels with NODAT in the present
study, we examined the association between these two covar-
iates. Hypomagnesemia is reported as occurring in 3–48% of
patients taking tacrolimus [35–37]. Calcineurin inhibition has
been implicated in hypomagnesemia via downregulation of
renal tubular calcium and magnesium reabsorption in several
previous studies [38–41]. We observed no significant associ-
ation between hypomagnesemia and high trough tacrolimus
levels, while a direct relationship between plasma magnesium
and trough tacrolimus levels was evident, albeit with a rela-
tively Bflat^ gradient. These observations, taken together with
the Cox proportional hazards model, suggest that hypomag-
nesemia is an independent risk factor for NODAT, with tacro-
limus being a separate independent risk factor.
There are several motivations to urgently find effective
interventions to reduce the risk of developing NODAT in chil-
dren. NODAT presents particular challenges in the pediatric
population. Glycemic control is challenging to achieve in
growing children and adolescents [42, 43]. Adolescence itself
is a potent risk factor for renal transplant loss, probably due to
variable adherence to immunosuppressive medication [44].
Concordance with prescribed insulin and blood glucose mon-
itoring in addition to transplant immunosuppression and fluid
regimens is difficult for even the most motivated families. The
burden of cardiovascular disease in pediatric kidney transplant
recipients is substantial, with significant additional cumulative
cardiovascular risk from NODAT in affected children.
Effective interventions to reduce this risk are needed.
Hypomagnesemia is a potentially modifiable risk factor for
NODAT. Supplementation of magnesium in adult kidney
transplant recipients was found to improve fasting blood glu-
cose levels 3 months post-transplant in a randomized study
[45]. The effect of magnesium supplementation on the risk of
NODAT remains unclear as this study was not powered to
evaluate this. Given the well-established relationship of
NODAT with hypomagnesemia, a well-powered study to
evaluate the effect of magnesium supplementation on
NODAT risk in adult and pediatric kidney transplant recipi-
ents is merited.
This study has a number of limitations. Firstly, its retro-
spective design limits the completeness of data and the ability
to apply rigorous entry criteria. This weakness was mitigated
in part by using a large volume of electronic test results for
analyses exported from a clinical laboratory system. Secondly,
relative to studies on adult kidney transplant recipients, the
number of participants is small at 173, which limits the impact
of the findings somewhat. The results obtained were neverthe-
less clinically significant. Thirdly, genetic testing was not per-
formed on all patients, which limited the assessment of the
contribution HNF-1B mutations to both hypomagnesemia
and NODAT. Notwithstanding these limitations, these data
clearly demonstrate a significant association between hypo-
magnesemia and NODAT in children.
This study identifies a clear association between hypomag-
nesemia and NODAT in children following kidney transplan-
tation. Further work is needed to determine the exact etiology
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of this association, in particular the genetic contribution from
candidate genes such as HNF-1B. Given the evidence of the
link between NODATand hypomagnesemia in both adult and
children following renal transplantation, interventional studies
to understand the effect of magnesium supplementation on
NODAT risk are merited.
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